Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Investing Activities (2016 - 2025)

United Therapeutics' Cash from Investing Activities history spans 17 years, with the latest figure at -$227.6 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 84.74% year-over-year to -$227.6 million; the TTM value through Dec 2025 reached -$551.3 million, down 232.14%, while the annual FY2025 figure was -$551.3 million, 232.14% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$227.6 million at United Therapeutics, down from $140.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $735.3 million in Q1 2024 and bottomed at -$359.2 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$166.9 million (2022), against an average of -$107.6 million.
  • The largest annual shift saw Cash from Investing Activities plummeted 5601.59% in 2022 before it skyrocketed 432.56% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$195.8 million in 2021, then rose by 3.32% to -$189.3 million in 2022, then soared by 122.24% to $42.1 million in 2023, then tumbled by 392.64% to -$123.2 million in 2024, then tumbled by 84.74% to -$227.6 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Cash from Investing Activities are -$227.6 million (Q4 2025), $140.9 million (Q3 2025), and -$299.9 million (Q2 2025).